228 reports of this reaction
1.7% of all EPTINEZUMAB JJMR reports
#11 most reported adverse reaction
NASAL CONGESTION is the #11 most commonly reported adverse reaction for EPTINEZUMAB JJMR, manufactured by Lundbeck Pharmaceuticals LLC. There are 228 FDA adverse event reports linking EPTINEZUMAB JJMR to NASAL CONGESTION. This represents approximately 1.7% of all 13,519 adverse event reports for this drug.
Patients taking EPTINEZUMAB JJMR who experience nasal congestion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL CONGESTION is a less commonly reported adverse event for EPTINEZUMAB JJMR, but still significant enough to appear in the safety profile.
In addition to nasal congestion, the following adverse reactions have been reported for EPTINEZUMAB JJMR:
The following drugs have also been linked to nasal congestion in FDA adverse event reports:
NASAL CONGESTION has been reported as an adverse event in 228 FDA reports for EPTINEZUMAB JJMR. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL CONGESTION accounts for approximately 1.7% of all adverse event reports for EPTINEZUMAB JJMR, making it a notable side effect.
If you experience nasal congestion while taking EPTINEZUMAB JJMR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.